Investigational drug · Phase 2
GSK3862995B
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Bronchiectasis, Pulmonary Disease, Chronic Obstructive.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "GSK3862995B"
First trial start
2025
Oct 30, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GSK3862995B", any sponsor or status.
Conditions studied
As listed on its trial records.
- Bronchiectasis
- Pulmonary Disease, Chronic Obstructive
Approved drugs for the same conditions: Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "GSK3862995B" as an intervention, largest first.
- A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With BronchiectasisPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07201051 · 363 participants (planned) · Start Oct 30, 2025 · Primary completion May 4, 2027
Drug: GSK3862995B; Placebo · For: Bronchiectasis
Sites: Mobile, Alabama; Phoenix, Arizona; La Palma, California · 134 sites in all
- A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07915791 · 279 participants (planned) · Start Oct 29, 2026 · Primary completion Mar 7, 2029
Drug: GSK3862995B; GSK5784283 and 1 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Newport Beach, California; Miami, Florida; Derby, Kansas · 10 sites in all
- A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary DiseasePivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT06154837 · 127 participants · Start Nov 27, 2023 · Primary completion Dec 16, 2026
Drug: GSK3862995B; Placebo · For: Pulmonary Disease, Chronic Obstructive
Sites: Yuma, Arizona; Hialeah, Florida; Orange City, Florida · 31 sites in all
GlaxoSmithKlineGSK (GSK)
NCT06979518 · 30 participants · Start May 20, 2025 · Primary completion Apr 22, 2026
Drug: GSK3862995B; Placebo · For: Pulmonary Disease, Chronic Obstructive
Sites: Cypress, California; Las Vegas, Nevada
GlaxoSmithKlineGSK (GSK)
NCT07789899 · 24 participants (planned) · Start Aug 18, 2026 · Primary completion Sep 7, 2027
Drug: GSK3862995B · For: Pulmonary Disease, Chronic Obstructive
Sites: Cambridge, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Bronchiectasis
- ItepekimabREGN3500, SAR440340Phase 39 trials
Sanofi · Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps, Bronchiectasis
- VerducatibBI 1291583Phase 34 trials
Boehringer Ingelheim · Bronchiectasis, Chronic Obstructive Pulmonary Disease
- HSK31858Phase 33 trials
Haisco Pharmaceutical Group Co., Ltd. · Non-cystic Fibrosis Bronchiectasis, Asthma Bronchiale, Bronchiectasis
- CHF10196florensocatibPhase 31 trial
Chiesi Farmaceutici S.p.A. · Bronchiectasis
- CHF6333Phase 21 trial
Chiesi Farmaceutici S.p.A. · Bronchiectasis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.